Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

The Mitochondria-Targeted Methylglyoxal Sequestering Compound, MitoGamide, Is Cardioprotective in the Diabetic Heart.

Tate M, Higgins GC, De Blasio MJ, Lindblom R, Prakoso D, Deo M, Kiriazis H, Park M, Baeza-Garza CD, Caldwell ST, Hartley RC, Krieg T, Murphy MP, Coughlan MT, Ritchie RH.

Cardiovasc Drugs Ther. 2019 Dec 13. doi: 10.1007/s10557-019-06914-9. [Epub ahead of print]

PMID:
31654171
2.

Complement C5a Induces Renal Injury in Diabetic Kidney Disease Via Disruption in Mitochondrial Metabolic Agility.

Tan SM, Ziemann M, Thallas-Bonke V, Snelson M, Kumar V, Laskowski A, Nguyen TV, Huynh K, Clarke MV, Libianto R, Baker ST, Skene A, Power DA, MacIsaac RJ, Henstridge DC, Wetsel RA, El-Osta A, Meikle PJ, Wilson SG, Forbes JM, Cooper ME, Ekinci EI, Woodruff TM, Coughlan MT.

Diabetes. 2019 Oct 17. pii: db190043. doi: 10.2337/db19-0043. [Epub ahead of print]

PMID:
31624141
3.

Globally elevating the AGE clearance receptor, OST48, does not protect against the development of diabetic kidney disease, despite improving insulin secretion.

Zhuang A, Yap FYT, McCarthy D, Leung C, Sourris KC, Penfold SA, Thallas-Bonke V, Coughlan MT, Schulz BL, Forbes JM.

Sci Rep. 2019 Sep 20;9(1):13664. doi: 10.1038/s41598-019-50221-0.

4.

Dietary Advanced Glycation End Products: Digestion, Metabolism and Modulation of Gut Microbial Ecology.

Snelson M, Coughlan MT.

Nutrients. 2019 Jan 22;11(2). pii: E215. doi: 10.3390/nu11020215. Review.

5.

Modulation of the Gut Microbiota by Resistant Starch as a Treatment of Chronic Kidney Diseases: Evidence of Efficacy and Mechanistic Insights.

Snelson M, Kellow NJ, Coughlan MT.

Adv Nutr. 2019 Mar 1;10(2):303-320. doi: 10.1093/advances/nmy068.

PMID:
30668615
6.

Use of Readily Accessible Inflammatory Markers to Predict Diabetic Kidney Disease.

Winter L, Wong LA, Jerums G, Seah JM, Clarke M, Tan SM, Coughlan MT, MacIsaac RJ, Ekinci EI.

Front Endocrinol (Lausanne). 2018 May 22;9:225. doi: 10.3389/fendo.2018.00225. eCollection 2018. Review.

7.

Methods in renal research: Measurement of autophagic flux in the renal cortex ex vivo.

Higgins GC, Nguyen TV, Ramm G, Coughlan MT.

Nephrology (Carlton). 2018 Sep;23(9):815-820. doi: 10.1111/nep.13251.

PMID:
29504645
8.

Perinatal exposure to high dietary advanced glycation end products in transgenic NOD8.3 mice leads to pancreatic beta cell dysfunction.

Borg DJ, Yap FYT, Keshvari S, Simmons DG, Gallo LA, Fotheringham AK, Zhuang A, Slattery RM, Hasnain SZ, Coughlan MT, Kantharidis P, Forbes JM.

Islets. 2018 Jan 2;10(1):10-24. doi: 10.1080/19382014.2017.1405189. Epub 2017 Dec 22.

9.

Increased liver AGEs induce hepatic injury mediated through an OST48 pathway.

Zhuang A, Yap FY, Bruce C, Leung C, Plan MR, Sullivan MA, Herath C, McCarthy D, Sourris KC, Kantharidis P, Coughlan MT, Febbraio MA, Hodson MP, Watt MJ, Angus P, Schulz BL, Forbes JM.

Sci Rep. 2017 Sep 25;7(1):12292. doi: 10.1038/s41598-017-12548-4.

10.

NADPH Oxidase Nox5 Accelerates Renal Injury in Diabetic Nephropathy.

Jha JC, Banal C, Okabe J, Gray SP, Hettige T, Chow BSM, Thallas-Bonke V, De Vos L, Holterman CE, Coughlan MT, Power DA, Skene A, Ekinci EI, Cooper ME, Touyz RM, Kennedy CR, Jandeleit-Dahm K.

Diabetes. 2017 Oct;66(10):2691-2703. doi: 10.2337/db16-1585. Epub 2017 Jul 26.

11.
12.

Stirring the Pot: Can Dietary Modification Alleviate the Burden of CKD?

Snelson M, Clarke RE, Coughlan MT.

Nutrients. 2017 Mar 11;9(3). pii: E265. doi: 10.3390/nu9030265. Review.

13.

Challenging the dogma of mitochondrial reactive oxygen species overproduction in diabetic kidney disease.

Coughlan MT, Sharma K.

Kidney Int. 2016 Aug;90(2):272-279. doi: 10.1016/j.kint.2016.02.043. Epub 2016 May 20. Review.

PMID:
27217197
14.

Dietary Advanced Glycation End Products and Risk Factors for Chronic Disease: A Systematic Review of Randomised Controlled Trials.

Clarke RE, Dordevic AL, Tan SM, Ryan L, Coughlan MT.

Nutrients. 2016 Mar 1;8(3):125. doi: 10.3390/nu8030125. Review.

15.

Mapping time-course mitochondrial adaptations in the kidney in experimental diabetes.

Coughlan MT, Nguyen TV, Penfold SA, Higgins GC, Thallas-Bonke V, Tan SM, Van Bergen NJ, Sourris KC, Harcourt BE, Thorburn DR, Trounce IA, Cooper ME, Forbes JM.

Clin Sci (Lond). 2016 May;130(9):711-20. doi: 10.1042/CS20150838. Epub 2016 Feb 1.

PMID:
26831938
16.

Deficiency in Apoptosis-Inducing Factor Recapitulates Chronic Kidney Disease via Aberrant Mitochondrial Homeostasis.

Coughlan MT, Higgins GC, Nguyen TV, Penfold SA, Thallas-Bonke V, Tan SM, Ramm G, Van Bergen NJ, Henstridge DC, Sourris KC, Harcourt BE, Trounce IA, Robb PM, Laskowski A, McGee SL, Genders AJ, Walder K, Drew BG, Gregorevic P, Qian H, Thomas MC, Jerums G, Macisaac RJ, Skene A, Power DA, Ekinci EI, Wijeyeratne XW, Gallo LA, Herman-Edelstein M, Ryan MT, Cooper ME, Thorburn DR, Forbes JM.

Diabetes. 2016 Apr;65(4):1085-98. doi: 10.2337/db15-0864. Epub 2016 Jan 28.

17.

Effect of diet-derived advanced glycation end products on inflammation.

Kellow NJ, Coughlan MT.

Nutr Rev. 2015 Nov;73(11):737-59. doi: 10.1093/nutrit/nuv030. Epub 2015 Sep 15. Review.

PMID:
26377870
18.

Can Targeting the Incretin Pathway Dampen RAGE-Mediated Events in Diabetic Nephropathy?

Sourris KC, Yao H, Jerums G, Cooper ME, Ekinci EI, Coughlan MT.

Curr Drug Targets. 2016;17(11):1252-64. Review.

PMID:
26201485
19.

Nox-4 deletion reduces oxidative stress and injury by PKC-α-associated mechanisms in diabetic nephropathy.

Thallas-Bonke V, Jha JC, Gray SP, Barit D, Haller H, Schmidt HH, Coughlan MT, Cooper ME, Forbes JM, Jandeleit-Dahm KA.

Physiol Rep. 2014 Nov 3;2(11). pii: e12192. doi: 10.14814/phy2.12192. Print 2014 Nov 1.

20.

Ramipril inhibits AGE-RAGE-induced matrix metalloproteinase-2 activation in experimental diabetic nephropathy.

Fukami K, Yamagishi S, Coughlan MT, Harcourt BE, Kantharidis P, Thallas-Bonke V, Okuda S, Cooper ME, Forbes JM.

Diabetol Metab Syndr. 2014 Aug 13;6(1):86. doi: 10.1186/1758-5996-6-86. eCollection 2014.

22.

Mitochondrial dysfunction and mitophagy: the beginning and end to diabetic nephropathy?

Higgins GC, Coughlan MT.

Br J Pharmacol. 2014 Apr;171(8):1917-42. doi: 10.1111/bph.12503. Review.

23.

Metabolic benefits of dietary prebiotics in human subjects: a systematic review of randomised controlled trials.

Kellow NJ, Coughlan MT, Reid CM.

Br J Nutr. 2014 Apr 14;111(7):1147-61. doi: 10.1017/S0007114513003607. Epub 2013 Nov 13. Review.

PMID:
24230488
24.

Advanced glycation end products (AGEs) are cross-sectionally associated with insulin secretion in healthy subjects.

Forbes JM, Sourris KC, de Courten MP, Dougherty SL, Chand V, Lyons JG, Bertovic D, Coughlan MT, Schlaich MP, Soldatos G, Cooper ME, Straznicky NE, Kingwell BA, de Courten B.

Amino Acids. 2014 Feb;46(2):321-6. doi: 10.1007/s00726-013-1542-9. Epub 2013 Jul 6.

PMID:
23832534
25.

Deficiency in mitochondrial complex I activity due to Ndufs6 gene trap insertion induces renal disease.

Forbes JM, Ke BX, Nguyen TV, Henstridge DC, Penfold SA, Laskowski A, Sourris KC, Groschner LN, Cooper ME, Thorburn DR, Coughlan MT.

Antioxid Redox Signal. 2013 Aug 1;19(4):331-43. doi: 10.1089/ars.2012.4719. Epub 2013 Mar 1.

PMID:
23320803
26.

Glucose homeostasis can be differentially modulated by varying individual components of a western diet.

Forbes JM, Cowan SP, Andrikopoulos S, Morley AL, Ward LC, Walker KZ, Cooper ME, Coughlan MT.

J Nutr Biochem. 2013 Jul;24(7):1251-7. doi: 10.1016/j.jnutbio.2012.09.009. Epub 2013 Jan 11.

PMID:
23313044
27.

Advanced glycation end products augment experimental hepatic fibrosis.

Goodwin M, Herath C, Jia Z, Leung C, Coughlan MT, Forbes J, Angus P.

J Gastroenterol Hepatol. 2013 Feb;28(2):369-76. doi: 10.1111/jgh.12042.

PMID:
23173780
28.

Targeting the AGE-RAGE axis improves renal function in the context of a healthy diet low in advanced glycation end-product content.

Thallas-Bonke V, Coughlan MT, Tan AL, Harcourt BE, Morgan PE, Davies MJ, Bach LA, Cooper ME, Forbes JM.

Nephrology (Carlton). 2013 Jan;18(1):47-56. doi: 10.1111/j.1440-1797.2012.01665.x.

PMID:
23046363
29.

Advanced glycation end products as environmental risk factors for the development of type 1 diabetes.

Yap FY, Kantharidis P, Coughlan MT, Slattery R, Forbes JM.

Curr Drug Targets. 2012 Apr;13(4):526-40. Review.

PMID:
22250649
30.

Ubiquinone (coenzyme Q10) prevents renal mitochondrial dysfunction in an experimental model of type 2 diabetes.

Sourris KC, Harcourt BE, Tang PH, Morley AL, Huynh K, Penfold SA, Coughlan MT, Cooper ME, Nguyen TV, Ritchie RH, Forbes JM.

Free Radic Biol Med. 2012 Feb 1;52(3):716-723. doi: 10.1016/j.freeradbiomed.2011.11.017. Epub 2011 Nov 21.

PMID:
22172526
31.

Advanced glycation end products are direct modulators of β-cell function.

Coughlan MT, Yap FY, Tong DC, Andrikopoulos S, Gasser A, Thallas-Bonke V, Webster DE, Miyazaki J, Kay TW, Slattery RM, Kaye DM, Drew BG, Kingwell BA, Fourlanos S, Groop PH, Harrison LC, Knip M, Forbes JM.

Diabetes. 2011 Oct;60(10):2523-32. doi: 10.2337/db10-1033. Epub 2011 Sep 12.

32.

Advanced glycation urinary protein-bound biomarkers and severity of diabetic nephropathy in man.

Coughlan MT, Patel SK, Jerums G, Penfold SA, Nguyen TV, Sourris KC, Panagiotopoulos S, Srivastava PM, Cooper ME, Burrell LM, Macisaac RJ, Forbes JM.

Am J Nephrol. 2011;34(4):347-55. doi: 10.1159/000331064. Epub 2011 Aug 26.

33.

Temporal increases in urinary carboxymethyllysine correlate with albuminuria development in diabetes.

Coughlan MT, Forbes JM.

Am J Nephrol. 2011;34(1):9-17. doi: 10.1159/000328581. Epub 2011 Jun 6.

PMID:
21654162
34.

Targeted reduction of advanced glycation improves renal function in obesity.

Harcourt BE, Sourris KC, Coughlan MT, Walker KZ, Dougherty SL, Andrikopoulos S, Morley AL, Thallas-Bonke V, Chand V, Penfold SA, de Courten MP, Thomas MC, Kingwell BA, Bierhaus A, Cooper ME, de Courten B, Forbes JM.

Kidney Int. 2011 Jul;80(2):190-8. doi: 10.1038/ki.2011.57. Epub 2011 Mar 16.

35.

Receptor for advanced glycation end-products (RAGE) provides a link between genetic susceptibility and environmental factors in type 1 diabetes.

Forbes JM, Söderlund J, Yap FY, Knip M, Andrikopoulos S, Ilonen J, Simell O, Veijola R, Sourris KC, Coughlan MT, Forsblom C, Slattery R, Grey ST, Wessman M, Yamamoto H, Bierhaus A, Cooper ME, Groop PH.

Diabetologia. 2011 May;54(5):1032-42. doi: 10.1007/s00125-011-2058-z. Epub 2011 Feb 6. Erratum in: Diabetologia. 2011 Jun;54(6):1586-7.

PMID:
21298413
36.

miR-200a Prevents renal fibrogenesis through repression of TGF-β2 expression.

Wang B, Koh P, Winbanks C, Coughlan MT, McClelland A, Watson A, Jandeleit-Dahm K, Burns WC, Thomas MC, Cooper ME, Kantharidis P.

Diabetes. 2011 Jan;60(1):280-7. doi: 10.2337/db10-0892. Epub 2010 Oct 15.

37.

Antiatherosclerotic and renoprotective effects of ebselen in the diabetic apolipoprotein E/GPx1-double knockout mouse.

Chew P, Yuen DY, Stefanovic N, Pete J, Coughlan MT, Jandeleit-Dahm KA, Thomas MC, Rosenfeldt F, Cooper ME, de Haan JB.

Diabetes. 2010 Dec;59(12):3198-207. doi: 10.2337/db10-0195. Epub 2010 Sep 7.

38.

Receptor for AGEs (RAGE) blockade may exert its renoprotective effects in patients with diabetic nephropathy via induction of the angiotensin II type 2 (AT2) receptor.

Sourris KC, Morley AL, Koitka A, Samuel P, Coughlan MT, Penfold SA, Thomas MC, Bierhaus A, Nawroth PP, Yamamoto H, Allen TJ, Walther T, Hussain T, Cooper ME, Forbes JM.

Diabetologia. 2010 Nov;53(11):2442-51. doi: 10.1007/s00125-010-1837-2. Epub 2010 Jul 15.

39.

Preservation of kidney function with combined inhibition of NADPH oxidase and angiotensin-converting enzyme in diabetic nephropathy.

Thallas-Bonke V, Coughlan MT, Bach LA, Cooper ME, Forbes JM.

Am J Nephrol. 2010;32(1):73-82. doi: 10.1159/000314924. Epub 2010 Jun 11.

PMID:
20551625
40.

Circulating high-molecular-weight RAGE ligands activate pathways implicated in the development of diabetic nephropathy.

Penfold SA, Coughlan MT, Patel SK, Srivastava PM, Sourris KC, Steer D, Webster DE, Thomas MC, MacIsaac RJ, Jerums G, Burrell LM, Cooper ME, Forbes JM.

Kidney Int. 2010 Aug;78(3):287-95. doi: 10.1038/ki.2010.134. Epub 2010 May 12.

41.

Advanced glycation end-products induce vascular dysfunction via resistance to nitric oxide and suppression of endothelial nitric oxide synthase.

Soro-Paavonen A, Zhang WZ, Venardos K, Coughlan MT, Harris E, Tong DC, Brasacchio D, Paavonen K, Chin-Dusting J, Cooper ME, Kaye D, Thomas MC, Forbes JM.

J Hypertens. 2010 Apr;28(4):780-8. doi: 10.1097/HJH.0b013e328335043e.

PMID:
20186099
42.

Disparate effects on renal and oxidative parameters following RAGE deletion, AGE accumulation inhibition, or dietary AGE control in experimental diabetic nephropathy.

Tan AL, Sourris KC, Harcourt BE, Thallas-Bonke V, Penfold S, Andrikopoulos S, Thomas MC, O'Brien RC, Bierhaus A, Cooper ME, Forbes JM, Coughlan MT.

Am J Physiol Renal Physiol. 2010 Mar;298(3):F763-70. doi: 10.1152/ajprenal.00591.2009. Epub 2009 Dec 16.

43.

Serum carboxymethyllysine concentrations are reduced in diabetic men with abdominal aortic aneurysms: Health In Men Study.

Norman PE, Davis WA, Coughlan MT, Forbes JM, Golledge J, Davis TM.

J Vasc Surg. 2009 Sep;50(3):626-31. doi: 10.1016/j.jvs.2009.05.058. Epub 2009 Jul 22.

44.

RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes.

Coughlan MT, Thorburn DR, Penfold SA, Laskowski A, Harcourt BE, Sourris KC, Tan AL, Fukami K, Thallas-Bonke V, Nawroth PP, Brownlee M, Bierhaus A, Cooper ME, Forbes JM.

J Am Soc Nephrol. 2009 Apr;20(4):742-52. doi: 10.1681/ASN.2008050514. Epub 2009 Jan 21.

45.

Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes.

Soro-Paavonen A, Watson AM, Li J, Paavonen K, Koitka A, Calkin AC, Barit D, Coughlan MT, Drew BG, Lancaster GI, Thomas M, Forbes JM, Nawroth PP, Bierhaus A, Cooper ME, Jandeleit-Dahm KA.

Diabetes. 2008 Sep;57(9):2461-9. doi: 10.2337/db07-1808. Epub 2008 May 28.

46.

Oxidative stress as a major culprit in kidney disease in diabetes.

Forbes JM, Coughlan MT, Cooper ME.

Diabetes. 2008 Jun;57(6):1446-54. doi: 10.2337/db08-0057. Review.

47.

Cardiac inflammation associated with a Western diet is mediated via activation of RAGE by AGEs.

Tikellis C, Thomas MC, Harcourt BE, Coughlan MT, Pete J, Bialkowski K, Tan A, Bierhaus A, Cooper ME, Forbes JM.

Am J Physiol Endocrinol Metab. 2008 Aug;295(2):E323-30. doi: 10.1152/ajpendo.00024.2008. Epub 2008 May 13.

48.

Oxidative stress and advanced glycation in diabetic nephropathy.

Coughlan MT, Mibus AL, Forbes JM.

Ann N Y Acad Sci. 2008 Apr;1126:190-3. doi: 10.1196/annals.1433.018.

PMID:
18448815
49.

Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway.

Thallas-Bonke V, Thorpe SR, Coughlan MT, Fukami K, Yap FY, Sourris KC, Penfold SA, Bach LA, Cooper ME, Forbes JM.

Diabetes. 2008 Feb;57(2):460-9. Epub 2007 Oct 24.

50.

Role of the AGE crosslink breaker, alagebrium, as a renoprotective agent in diabetes.

Coughlan MT, Forbes JM, Cooper ME.

Kidney Int Suppl. 2007 Aug;(106):S54-60. Review.

Supplemental Content

Loading ...
Support Center